Predictive Oncology Inc represents values of innovation, precision, and expertise in the field of oncology. The company is dedicated to leveraging advanced technologies and data-driven analytics to develop personalized cancer therapies. With a focus on predictive modeling, Predictive Oncology aims to revolutionize cancer treatment by improving patient outcomes and reducing healthcare costs. Committed to staying at the forefront of scientific advancements, the company collaborates with leading institutions and experts in oncology research. By combining cutting-edge technology with deep domain knowledge, Predictive Oncology strives to empower healthcare providers and patients with tailored solutions for effective cancer management.

Predictive Oncology Inc is primarily present in the United States with its headquarters located in Minneapolis, Minnesota. As a leading precision medicine company, Predictive Oncology focuses on developing innovative solutions to improve cancer care and treatment.

Predictive Oncology Inc has achieved several significant milestones in the field of oncology. These include the development of innovative technology solutions for cancer research and personalized medicine. The company has successfully built a proprietary database with extensive molecular and clinical information, facilitating the discovery of key insights into cancer biology. Furthermore, Predictive Oncology has established strategic collaborations with leading research institutions and pharmaceutical companies to accelerate the development and validation of its novel approaches. The company's commitment to advancing precision medicine has resulted in notable achievements and recognition within the industry. Predictive Oncology Inc continues to strive towards improving patient outcomes and revolutionizing cancer treatment through cutting-edge discoveries and partnerships.

Predictive Oncology Inc, a leading healthcare company, has a rich history and remarkable background. With a focus on revolutionizing cancer treatment, the company operates through its subsidiaries to develop cutting-edge therapies and personalized medicine. Originally founded in 2002 as Precision Therapeutics, Predictive Oncology has since evolved to incorporate advanced data analytics and artificial intelligence to improve oncology outcomes. This innovative approach aims to identify effective drug combinations and provide insights into individual patient response, ultimately saving lives. Through its commitment to developing breakthrough solutions, Predictive Oncology Inc has emerged as a trailblazer in the field of oncology, continuously striving for advancements and better patient care.

The main competitors of Predictive Oncology Inc in the market include companies like Guardant Health Inc, Foundation Medicine Inc, and Tempus Labs.

Predictive Oncology Inc is primarily active in the healthcare and biotechnology industries.

Predictive Oncology Inc is a company with a business model focused on providing predictive and personalized medicine solutions for cancer patients. Their main goal is to use advanced technology and data analytics to improve the outcome of cancer treatments. Predictive Oncology Inc incorporates artificial intelligence, machine learning, and biomarker discovery to identify and develop effective treatment strategies. By analyzing molecular and genetic information, the company aims to assist physicians in making informed decisions and providing patients with personalized therapies. Through their innovative approach, Predictive Oncology Inc aims to revolutionize cancer care and contribute to better patient outcomes.

Коефициентът на цена спрямо печалбата (КЦП) на Predictive Oncology е -0,22.

Коефициентът на цена към оборот (KUV) на Predictive Oncology е 1,93.

AlleAktien качественият резултат за Predictive Oncology е 4/10.

очаквана Predictive Oncology оборотът е 1,58 млн. USD.

очаквана Predictive Oncology печалба е -13,81 млн. USD.

Predictive Oncology Inc is a company specializing in the development of predictive models to support personalized medicine in oncology. Its main goal is to offer more precise treatment options for cancer patients and thus improve cure rates. The business model of Predictive Oncology Inc consists of three main areas: (1) Predictive modeling of cancer, (2) services in the field of personalized medicine, and (3) production of medications. The predictive modeling of cancer performed by the company is based on the analysis of large datasets, including genetic, clinical, and molecular data from cancer patients. These data are then used to create predictive models that enhance the understanding of cancer biology and support personalized medicine. Predictive Oncology Inc also offers services in the field of personalized medicine based on the results of predictive modeling of cancer. These services include genetic tests that enable more precise cancer diagnosis, as well as consulting services for doctors to provide more precise treatment options based on the individual needs of the patient. The company also produces medications based on the results of predictive modeling of cancer. By utilizing genetic and molecular information, Predictive Oncology Inc can develop medications specifically tailored to the needs of cancer patients to ensure higher effectiveness and fewer side effects. Overall, Predictive Oncology Inc provides a comprehensive solution to the problem of personalized medicine in oncology. By integrating predictive modeling, personalized services, and the production of specialized medications, the company can offer more precise treatment options tailored to the needs of each individual patient. The customers of Predictive Oncology Inc are doctors, hospitals, and laboratories in need of services in the field of personalized medicine, as well as pharmaceutical companies interested in the development of specialized cancer medications. As a leading company in the field of personalized medicine in oncology, Predictive Oncology Inc has a strong market presence and is well-positioned to benefit from the growing demand for more precise treatment options in cancer medicine. Overall, the business model of Predictive Oncology Inc is a unique combination of predictive modeling, personalized services, and the production of specialized medications. By providing more precise treatment options, the company can contribute to improving cure rates in cancer and prolonging patients' lives.

Predictive Oncology разпределя дивидента от 0 USD на плащания годишно.

Дивидентата за Predictive Oncology в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на Predictive Oncology е US74039M2008.

WKN на Predictive Oncology е A2PUKH.

Тикерът на Predictive Oncology е POAI.

През последните 12 месеца Predictive Oncology изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква Predictive Oncology да изплати дивиденда в размер на 0 USD.

Дивидентната доходност на Predictive Oncology в момента е .

Predictive Oncology изплаща дивидент на тримесечие. Той се разпределя в месеците .

Predictive Oncology платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 USD. Това съответства на дивидентна доходност от 0 %.

Predictive Oncology се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от Predictive Oncology на 28.09.2024 г. в размер на 0 USD, трябваше да притежавате акцията в портфейла си преди Ex-деня на 28.09.2024 г..

Последното дивидентно плащане беше извършено на 28.09.2024 г..

През година 2023 Predictive Oncology изплати 0 USD под формата на дивиденти.

Дивидентите от Predictive Oncology се изплащат в USD.